RECURRENT ENDOMETRIAL CARCINOMA

This early-stage study tests a drug called talazoparib combined with radiation therapy for people whose gynecologic cancer (like ovarian, uterine, or cervical) has returned. The goal is to find the safest dose and see if the combination can shrink tumors. About 24 participants wi…

This study is for women whose ovarian or endometrial cancer has returned or not gone away and has a specific change in the RAS gene. It compares two treatments: a drug called selumetinib alone versus selumetinib combined with olaparib. The goal is to see if the combination can sh…

This early-phase study tests two experimental drugs (M1774 and ZEN-3694) together in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see how well the combination works. About 65 participants will take part to help determine if this…

This study tests whether adding a drug called bevacizumab to standard chemotherapy and immunotherapy can better control advanced or recurrent endometrial cancer in people with specific gene changes (pMMR and TP53 mutated). About 255 participants will receive one of three treatmen…

This early-phase study tests whether combining two cancer drugs (lenvatinib and pembrolizumab) with a short course of pelvic radiation is safe and effective for people with recurrent or inoperable endometrial cancer. About 18 participants will receive the treatment to find the be…

This study is for people with a type of recurrent endometrial cancer that has a specific DNA repair problem (called dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against one drug alone (nivolumab) to see which shrinks tumors better. About …

This study tests whether combining two drugs—avelumab (an immunotherapy) and M1774 (a targeted pill)—can shrink or slow the growth of recurrent endometrial cancer in people whose tumors have a specific genetic change (ARID1A mutation). About 25 participants will receive the combi…

This study tests a combination of two drugs, nab-sirolimus and letrozole, in people with advanced or recurrent endometrioid endometrial cancer. The goal is to see if the combination can shrink or control tumors. About 29 participants will receive the treatment, and researchers wi…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This study screens people with advanced solid tumors to see if their cancer has specific genetic changes. Based on those results, they may be matched to a treatment trial that targets their tumor's unique genetics. The goal is to learn how well these targeted combinations work an…